View Author
hbeag seroconversion hbeag liver patient seroconversion expression tumor level therapy hepatocellular carcinoma nucleo treatment recurrence hepatitis carcinoma study analogue factor tissue growth follow-up evaluation vegfr hepatocellular protein hepatitis b angiogenic hepatology cirrhotic sample virologic analysis follow-up cirrhotic livers month cancer noncirrhotic durability virologic recurrence response angiopoietin serologic ang -2 subject hbv-dna vegf-a angiogenesi –liver pancreas 6 months evaluation hbv-dna levels /or virologic recurrence hbsag receptor lamivudine growth factor noncirrhotic livers gastroenterology serum infection rt-pcr antibody blot analysis virus development kidney hepatitis b patients serologic recurrence antigen assay relapse signi monotherapy protein expression consolidation therapy control hbv infection tie -2 system range lam monotherapy
2 Most Recent Publications
|
Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B
(Article)
Reijnders, J.G.P. Perquin, M.J. Zhang, N. Hansen, B.E. Janssen, H.L.A. |
2010-08-17
|
|
The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization
(Article)
Zeng, W. Gouw, A.S.H. Heuvel, M.C. van den Zwiers, P.J. Zondervan, P.E. Poppema, S. Zhang, N. Platteel, I. Jong, K.P. de Molema, G. |
2008-11-01
|